Trials / Recruiting
RecruitingNCT06673238
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
A First-In-Human Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-722 Following Single and Multiple Ascending Doses in Healthy Adult Subjects and Single Doses in Healthy Adult Asian Subjects
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, first-in-human study to investigate safety, tolerability, and pharmacokinetics of ABBV-722 after oral dosing in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-722 | Oral Capsule |
| DRUG | Placebo | Oral Capsule |
Timeline
- Start date
- 2024-10-29
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2024-11-04
- Last updated
- 2025-07-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06673238. Inclusion in this directory is not an endorsement.